Antiphospholipid Antibodies in Patients with Lupus Nephritis

References

• Gharavi A.E., Harris E.N., Asherson R.A., Hughes G.R.V. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann. Rheum. Dis. 1987; 46: 1–6
   Google Scholar
• Falcon C.R., Hoffer A.M., Carreras L.O. Antiphosphatidylinositol antibodies as markers of the antiphospholipid syndrome. Thromb. Haemost. 1990; 63: 321–322
   Google Scholar
• Berard M., Chantome R., Marcelli A., Boffa M.C. Anti-phosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J. Rheumatol. 1996; 23: 1369–1374
   Google Scholar
• Branch D.W., Silver R., Pierangeli S., van Leeuwen I., Harris E.N. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet. Gynecol. 1997; 89: 549–555
   Google Scholar
• Harris E.N., Pierangeli S.S., Gharavi A.E. Diagnosis of the antiphospholipid syndrome: a proposal for use of laboratory tests. Lupus 1998; 7(suppl 2)144–148
   Google Scholar
• Cabral A.R., Cabiedes J., Alacron-Segovia D. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. J. Autoimmun. 1990; 3: 773–787
   Google Scholar
• Roubey R.A.S., Eisenberg R., Harper M.F., Winfield J.B. Anticardiolipin autoantibodies recognize β2-glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding. J. Immunol. 1995; 154: 954–960
   Google Scholar
• Bevers E.M., Galli M., Barbui T., Comfurius P., Zwaal R.F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb. Hemost. 1991; 66: 629–632
   Google Scholar
• Shoenfeld Y., Gharavi A., Koike T. β2GPI in the antiphospholipid (Hughes′) syndrome—from a cofactor to an autoantigen—from induction to prevention of antiphospholipid syndrome. Lupus 1998; 7: 503–506
   Google Scholar
• Sheng Y., Kandiah D.A., Krilis S.A. β2-Glycoprotein I: target antigen for antiphospholipid antibodies. Immunological and molecular aspects. Lupus 1998; 7(suppl 2)S5–S9
   Google Scholar
• Schousboe I. Beta-2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086–1091
   Google Scholar
• Nimpf J., Bevers E.M., Bomans P.H., Till V., Wurm H., Kostner G.M., Zwaal R.F. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim. Biophys. Acta 1986; 884(1)142–149
   Google Scholar
• Nimpf J., Wurm H., Kostner G.M. β2-Glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109–114
   Google Scholar
• Shi W., Chong B.H., Chesterman C.N. β2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255–1262
   Google Scholar
• Chamley L.W. Antiphospholipid antibodies or not? The role of β2-glycoprotein I in autoantibody-mediated pregnancy loss (review). J. Reprod. Immunol. 1997; 36: 123–142
   Google Scholar
• Harper M.F., Lentz B.R., Roubey R.A.S. β2-Glycoprotein I (β2GPI) binding to phospholipid (PL) membranes. Lupus 1996; 5: 522
   Google Scholar
• Price B.E., Rauch J., Shia M.A., Walsh M.T., Lieberthal W., Gilligan H.M., o'Laughalin T., Koh J.S., Levine J.S. Anti-phospholipid antibodies bind apoptotic but not to viable, thymocytes in a β2-glycoprotein I—dependent manner. J. Immunol. 1996; 157: 2201–2208
   Google Scholar
• Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177–178
   Google Scholar
• Vaarala O., Puurunen M., Lukka M., Alfthan G., Leirisalo-Repo M., Aho K., Palosuo T. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin. Exp. Immunol. 1996; 104(2)269–274
   Google Scholar
• Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 1997; 107(3)569–673
   Google Scholar
• Hörkkö S., Miller E., Branch D.W., Palinski W., Witztum J.L. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and β2-glycoprotein I (and other proteins). Proc. Natl. Acad. Sci. USA 1997; 94: 10356–10361
   Google Scholar
• Harris E.N. Antiphospholipid antibodies. Br. J. Hematol. 1990; 74: 1–9
   Google Scholar
• Hughes G.R. Hughes′ syndrome: the antiphospholipid syndrome. A historical view. Lupus 1998; 7(suppl 2)S1–S4
   Google Scholar
• Piette J.C. Towards improved criteria for the antiphospholipid syndrome. Lupus 1998; 7(suppl 2)S149–S157
   Google Scholar
• Fialová L., Mikulíková L., Malbohan I.M., Benešová O., Zwinger A. Prevalence of various antiphospholipid antibodies in pregnant women. Physiol. Res. 2000; 49: 299–305
   Google Scholar
• Zima T., Fialová L., Mikulíková L., Malbohan I.M., Popov P., Nešpor K. Antibodies against phospholipids and oxidized LDL in alcoholic patients. Physiol. Res. 1998; 47: 351–355
   Google Scholar
• McNeil H.P., Chesterman C.N., Krilis S.A. Immunology and clinical importance of anticardiolipin antibodies. Adv. Immunol. 1991; 49: 193–280
   Google Scholar
• Bevers E., Comfrius P., van Rijn J., Hemker C., Zwaal R. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur. J. Biochem. 1982; 122: 429–436
   Google Scholar
• Hunt J., Krilis S. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys 281–Cys 288) and a region recognized by anticardiolipin antibodies. J. Immunol. 1994; 52: 653–659
   Google Scholar
• Matsuura E., Katahira T., Igarashi Y., Koike T. β2-Glycoprotein I bound to oxidatively modified lipoproteins could be targeted by anticardiolipin antibodies. Lupus 1994; 3: 314–317
   Google Scholar
• Hörkkö S., Miller E., Dudl E., Reaven R.V., Curtiss L.K., Zvaifler N., Terkeltaub R., Pierangeli S.S., Branch D.W., Palinski W., Witztum J.L. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipid. J. Clin. Invest. 1996; 98(3)815–825
   Google Scholar
• Vaarala O. Autoantibodies to modified LDLs and other phospholipid–protein complexes as markers of cardiovascular diseases. J. Inter. Med. 2000; 24: 381–384
   Google Scholar
• Urowitz M.B., Gladman D.D. Accelerated atheroma in lupus—background (review). Lupus 2000; 9: 161–165
   Google Scholar
• Iuliano L., Pratico D., Ferro D., Pittoni V., Valesini G., Lawson J., FitzGerald G.A., Violi F. Enhanced lipid peroxidation in patients positive for antiphosholipid antibodies. Blood 1997; 90: 3931–3935
   Google Scholar
• George J., Afek A., Gilburd B., Levy Y., Blank M., Kopolovic J., Harats D., Shoenfeld Y. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997; 6(9)723–729
   Google Scholar
• Shoenfeld Y., Harats D., George J. Atheroslerosis and the antiphospholipid syndrome. A link unravelled. Lupus 1998; 7(suppl 2)S140–S143
   Google Scholar
• Viard J.P., Amoura Z., Bach J.F. Association of anti-β2-glycoprotein I antibodies with lupus type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am. J. Med. 1992; 93: 181–186
   Google Scholar
• Romero F.I., Amengual O., Atsumi T., Khamashta M.A., Tinahones F.J., Hughes G.R. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-β2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol. 1998; 37: 883–888
   Google Scholar